Studies

Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.

JCEM case reports|2025|Shah I, Sennik D, Veettil F

Tirzepatide (Mounjaro), a novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly prescribed for type 2 diabetes and off-label weight loss. While gastrointestinal adverse ef…

Case ReportTirzepatide

PMID: 41179268

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease.

Diabetes research and clinical practice|2025|Hong A et al.

AIMS: To compare the association of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and dipeptidyl peptidase-4 inhibitors (DPP-4i) therapies on lower extremity vascular complications and mortal…

Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie|2025|Fahim S et al.

Obesity and diabetes are two faces of the same coin, as both disorders are characterized by insulin action defects. The two gut-derived incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1), play a…

ReviewSemaglutide Tirzepatide

PMID: 41177120

Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

Diabetes & metabolic syndrome|2025|Courtney L et al.

AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of C…

ReviewSemaglutide Tirzepatide

PMID: 41176849

[In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.].

Recenti progressi in medicina|2025|Serafini A, Ebell M, Liberali C

Semaglutide Tirzepatide

PMID: 41176671

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.

Journal of endocrinological investigation|2025|Tuccinardi D et al.

OBJECTIVE: Obesity is a biologically complex and heterogeneous disease that requires individualized, phenotype- and complication-oriented therapeutic strategies. The introduction of advanced pharmacotherapies, including GLP-1 receptor agonists (GLP-1…

ReviewSemaglutide Tirzepatide

PMID: 41212412

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.

Journal of obesity|2025|Velji-Ibrahim J et al.

OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…

ReviewSemaglutide Tirzepatide

PMID: 41211586

Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.

Obesity pillars|2025|Eason K, Feeney C, Killeen T

INTRODUCTION: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, produces substantial weight loss and glycaemic improvement in people with and without type 2 diabetes mellitus…

Case ReportTirzepatide

PMID: 41211573

Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.

Cureus|2025|Ahern S

Semaglutide and tirzepatide are two commonly prescribed glucagon-like peptide-1 (GLP-1) and GLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonists used for the treatment of type 2 diabetes and chronic weight management. Allo…

Case ReportSemaglutide Tirzepatide

PMID: 41210042

Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.

Cureus|2025|Dutta N et al.

OBJECTIVE: We assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiovascular events (MACE) compared to metabolic and bariatric surgery (MBS) and usual care (UC). METHODS: We retros…

Semaglutide Tirzepatide

PMID: 41209894

The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.

Expert opinion on drug safety|2025|Hoffmann K et al.

BACKGROUND: Tirzepatide has shown benefits in weight reduction and glycemic control in type 2 diabetes and obesity, but its relative efficacy and safety across doses remain unclear. METHODS: We conducted a PROSPERO-registered systematic review and ne…

ReviewTirzepatide

PMID: 41200927

Cardiovascular efficacy of tirzepatide: what real-world evidence promises.

Expert review of cardiovascular therapy|2025|Nasoufidou A et al.

Tirzepatide

PMID: 41199614

Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.

Archives of pharmacal research|2025|Kim H et al.

We previously developed LJ-4378, a dual ligand for Aand Aadenosine receptors, as a potential anti-obesity agent. In this study, we compared the anti-obesity effects of LJ-4378 with those of tirzepatide (TZP), a dual agonist of glucagon-like peptide-1…

Animal StudyTirzepatide

PMID: 41199017

From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.

Frontiers in endocrinology|2025|Chianelli M et al.

INTRODUCTION: Early treatment of obesity is essential and requires proactive engagement from healthcare providers. A 2022 survey among the members of the Italian Association of Clinical Endocrinologists (AME) revealed that they often did not address…

Semaglutide Tirzepatide

PMID: 41244051

Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?

Journal of the European Academy of Dermatology and Venereology : JEADV|2025|Gisondi P et al.

Tirzepatide

PMID: 41239939

Tirzepatide-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Presenting With Seizures.

Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease.

Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management.

Compounded incretins in clinical practice: An opinion of the endocrine and metabolism practice and research network of the American College of Clinical Pharmacy.

[In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.].

Letter by Zhao et al Regarding Article, "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity".

Response by Zile et al to Letter Regarding Article, "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity".

Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.

Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report.

Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.

Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.

Trump strikes deal with Ozempic and Mounjaro makers to cut prices of obesity injections.

The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.

Cardiovascular efficacy of tirzepatide: what real-world evidence promises.

Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.

Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spot.

From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.

Comment on "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients".

Tirzepatide in obese patients with psoriasis on biological therapy: Is this a window of opportunity?